Target intelligence / Profile preview

UBE2F-SCLY readthrough (UBE2F-SCLY)

Target: UBE2F-SCLY
Molecular classification: Other (RNA gene; chimeric readthrough, not protein-coding)

Overview

UBE2F-SCLY represents a naturally occurring read-through transcription event between the neighboring UBE2F (ubiquitin-conjugating enzyme E2F) and SCLY (selenocysteine lyase) genes located on chromosome 2. This transcript is a candidate for nonsense-mediated mRNA decay (NMD) and is unlikely to produce a functional protein product. Gene ontology annotations for UBE2F-SCLY suggest affiliation with RNA and/or non-coding RNA classes rather than with a protein-coding or functional therapeutic target. There is no evidence that UBE2F-SCLY functions as a receptor, enzyme, transporter, or any established therapeutic target[1][7].

Other names: UBE2F-SCLY readthroughUBE2F-SCLY

Beyond the preview

Go deeper on UBE2F-SCLY readthrough (UBE2F-SCLY).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBE2F-SCLY readthrough (UBE2F-SCLY).

Explore the full profile